Protagonist Therapeutics, Inc.
PTGX
$86.63
$1.982.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 209.22M | 209.18M | 207.80M | 434.43M | 323.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.22M | 209.18M | 207.80M | 434.43M | 323.80M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 209.22M | 209.18M | 207.80M | 434.43M | 323.80M |
| SG&A Expenses | 42.37M | 41.40M | 40.29M | 43.46M | 42.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 190.21M | 185.20M | 180.58M | 181.59M | 174.68M |
| Operating Income | 19.01M | 23.98M | 27.22M | 252.84M | 149.11M |
| Income Before Tax | 48.07M | 53.78M | 57.09M | 279.41M | 173.08M |
| Income Tax Expenses | 2.16M | 1.74M | 894.00K | 4.22M | 2.23M |
| Earnings from Continuing Operations | 45.91 | 52.04 | 56.19 | 275.19 | 170.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.91M | 52.04M | 56.19M | 275.19M | 170.85M |
| EBIT | 19.01M | 23.98M | 27.22M | 252.84M | 149.11M |
| EBITDA | 20.03M | 24.87M | 28.05M | 253.67M | 150.07M |
| EPS Basic | 0.76 | 0.84 | 0.89 | 4.48 | 2.82 |
| Normalized Basic EPS | 0.50 | 0.54 | 0.57 | 2.84 | 1.79 |
| EPS Diluted | 0.63 | 0.71 | 0.76 | 4.21 | 2.66 |
| Normalized Diluted EPS | 0.42 | 0.46 | 0.48 | 2.67 | 1.69 |
| Average Basic Shares Outstanding | 252.58M | 250.57M | 248.37M | 246.26M | 244.32M |
| Average Diluted Shares Outstanding | 256.65M | 254.65M | 252.44M | 253.08M | 248.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |